An observational study in Pulmonary Embolism, sponsored by Arianna Anticoagulazione Foundation. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-03-19.
Sponsored by Arianna Anticoagulazione Foundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Pulmonary Embolism with a site in Italy — 6 open to participants now, 8 under way, 1 of them phase 3. Pulmonary Embolism · Italy.
Among the 57 studies in Pulmonary Embolism with a site in Italy, this one is the 21st largest by enrollment of the 28 observational ones that give a count, is one of 4 that started in 2018, is one of 28 observational ones, and was the 45th registered.
833 studies on the registry are indexed under Pulmonary Embolism; 172 are open to participants now.
Browse Pulmonary Embolism studies →6 of the 57 studies in Pulmonary Embolism with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy, Poland, Spain
Ages 18+
Azienda ULSS 8 Berica · Sites in Italy
Ages 18+
Inari Medical · Sites in Italy, France, Germany and 2 more countries
Ages 18+
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
Niguarda Hospital · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 130 Pulmonary Embolism studies recruiting now, 110 (85%) set no upper age limit and 5 (4%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 19 · Phase 4 2
First in 1998; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 400 is above the median of 361 across 366 observational studies indexed under Pulmonary Embolism.
Median enrollment 656 across the 28 interventional studies, 623 across the 28 observational. Of the 44 that completed or were terminated, 11 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 57 have an industry lead sponsor. The 10 most frequent:
Arianna Anticoagulazione Foundation is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Arianna Anticoagulazione Foundation has 2 studies filed under Pulmonary Embolism — fewer than ten, so there is no comparison to draw.
3 of the studies in Pulmonary Embolism with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06143969Niguarda HospitalUltrasound-assisted, Catheter-directed Thrombolysis for Acute Intermediate-high-risk Pulmonary Embolism | 2026-11-30 |
| NCT04798261Penumbra Inc.Study of the Long-Term Safety and Outcomes of Treating Pulmonary Embolism With the Indigo Aspiration System | 2026-12 |
| NCT06761144IRCCS Azienda Ospedaliero-Universitaria di BolognaPulmonary Thromboembolism in Cancer Patients: Early Rule-out From the Emergency Department | 2027-07-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 57 studies in Pulmonary Embolism with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PEDIS Study is an observational, cross-sectional, multicenter Italian study conducted in a consecutive series of patients who refer to the Emergency Departments (either spontaneously or sent by their attending physicians) for the recent (less than one months) development of exertional dyspnea.
The general aim of the study is to assess the prevalence of PE in the overall population referring to the Emergency Departments without potential explanations for dyspnea
PEDIS Study is an observational, cross-sectional, multicenter and no Profit Study.
600 consecutive patients referring to the Emergency Departments of the participating centers because they have developed one or more episodes of exertional dyspnea since less than one month will be enrolled. All eligible patients will be interviewed and examined by trained study physicians. The presence of already known potential explanations for the dyspnea will be assessed. In addition, symptoms of the lower extremities will be elicited, as well as the presence of risk factors for venous thromboembolism (VTE).
The presence or absence of pulmonary embolism will be assessed with the use of a validated algorithm based on pre-test clinical probability and D-dimer result. In patients in whom the pre-test clinical probability is low and the D-dimer result is negative, no further testing will be done, and PE will be considered excluded. In patients with high clinical probability, positive D-dimer result, or both, computed tomography (CT) pulmonary angiography will be performed
The primary study objective is to evaluate Prevalence of PE in the overall population
All consecutive patients who refer to the Emergency Departments of the participating centers will be eligible for the study provided they are older than 18 and younger than 75 years, and have developed one or more episodes of exertional dyspnea since less than one month.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Prevalence of PE in the overall population
Prevalence of Pulmonary Embolism in patient with high pre-test clinical probability and/or positive D-dimer without potential explanations for the dyspnea who underwent computed tomography pulmonary angiography
Time frame: From the first day of enrollment up to 104 weeks
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Dec 2020, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arianna Anticoagulazione Foundation